Firms
Theme

STE

STERIS plc · NYSE

News

3 latest

Zacks Investment Research

Reasons to Add STE Stock to Your Portfolio Right Now

STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.

GlobeNewswire Inc.

STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety

STERIS plc announced a definitive agreement to acquire Xodus Medical, a specialty surgical products company, for $2.1 billion (net purchase price ~$1.8 billion after tax benefits). The acquisition is expected to close by December 31, 2026, and includes potential earnout consideration up to $150 million.

Mentions STE

GlobeNewswire Inc.

China Sterilization Equipment Market Outlook to 2033 - Chemical, Physical and Ultraviolet Sterilizers | Revenue, Volume and Pricing Trends Reveal Growth Opportunities

ResearchAndMarkets.com released a comprehensive market report on China's sterilization equipment industry covering chemical, physical, and ultraviolet sterilizers. The report provides revenue, volume, and pricing data from 2018-2033, competitive analysis of major players, and strategic insights for market entry and expansion in this growing sector.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $STE · 0 threads

Sign in to post on $STE

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev